Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingaron in Community-acquired Pneumonia
NCT05395702Completed
- Sponsor
- SPP Pharmaclon LTD
- Start
- May 2017
- Primary completion
- Jul 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of Ingaron in community acquired pneumonia (CAP) (2 arms), sponsored by SPP Pharmaclon LTD. Primary endpoint: Time to clinical stabilization of the patient's condition at Day 33. Started May 2017; status: completed.
02
Drugs
Ingaron
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT05395702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395702.